Traws Pharma Inc Dossier - Source-backed chat

Traws Pharma Inc

TRAWNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.38

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.59Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $9.1M

Enterprise Value $4.1M

Shares Outstanding 14M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Traws Pharma is a clinical-stage biopharmaceutical company focused on developing oral small-molecule antivirals for respiratory viral infections, including influenza and COVID-19. While the company recently secured a $60 million PIPE financing structure, its near-term clinical milestones have been severely disrupted. In June 2026, the UK MHRA issued a negative review of its lead influenza candidate, tivoxavir marboxil (TXM), deferring the planned Phase 2a human challenge study. This setback follows an existing FDA clinical hold on the U.S. IND due to mutagenicity and toxicology concerns. Consequently, the milestone-based warrants tied to the PIPE financing are compromised, leaving the company to rely on its cash runway through Q1 2027 while pivoting to backup candidates. Given these regulatory roadblocks, a Hold recommendation is advised until there is clear regulatory resolution or clinical progress with backup assets.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.00

Mean target$1.00

High · most bullish analyst$1.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The clinical hold on TXM becomes permanent due to unresolved toxicology issues, and backup candidates fail to replicate the desired pharmacokinetic profile. The company is unable to access additional tranches of the PIPE financing, leading to severe liquidity distress as the cash runway approaches Q1 2027, forcing highly dilutive equity raises or operational halts.

Base CaseCentral scenario

The company successfully engages with the FDA and UK MHRA to address mutagenicity concerns, or successfully transitions its development focus to backup influenza candidates that exclude mutagenic potential. The cash runway is managed prudently through Q1 2027, and the company secures non-dilutive funding or partnerships for its paused oncology assets (rigosertib and narazaciclib).

Bull CaseUpside scenario

The bull case for Traws Pharma centers on its strategic pivot to virology and its negative-strand RNA virus platform. Key drivers include the potential of tivoxavir marboxil as a once-monthly influenza prophylaxis or stockpile asset, and ratutrelvir as a ritonavir-free COVID-19 oral antiviral. Additionally, the company's expansion into outbreak-driven indications with limited treatment options, such as hantavirus and Ebola, provides longer-term optionality. This pipeline is supported by a cash runway extending into Q1 2027, bolstered by a private placement (PIPE) financing of up to $60 million in total potential gross proceeds.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated product profile with long-acting, single-dose potential for influenza prophylaxis.
Up to $60 million PIPE financing structure established in April 2026, providing a framework for funding if milestones are met.
Active pipeline diversification into high-unmet-need areas such as Hantavirus and Ebola.

Key Investment Risks

Lead asset tivoxavir marboxil is on clinical hold by the FDA and has been deferred by the UK MHRA due to mutagenicity and toxicology concerns.
Substantial doubt about the company's ability to continue as a going concern without unlocking milestone-based financing or securing new capital.
High dependency on early-stage clinical outcomes and regulatory approvals in a highly competitive antiviral market.

Thesis Invalidation Triggers

Failure to resolve the FDA clinical hold on tivoxavir marboxil by the end of 2026.
Inability to advance backup influenza candidates into clinical trials within the projected cash runway.
Exhaustion of cash reserves before securing additional non-milestone-based financing.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.